The global tissue engineering market accounted for USD 16.96 billion in 2023 and is expected to reach at USD 73.71 billion by 2034 with a CAGR of 14.29% during the forecast period 2024-2034. Growing prevalence of chronic disorders such as orthopedic disorders, diabetes, & cardiovascular diseases, surge in advancements related to biomaterials, 3D bioprinting, stem cell research, & gene editing techniques, rise in regeneration treatments, ongoing pre-clinical research is centered on using tissue-engineered vascular grafts for cardiovascular surgery & treatment, increasing technological progress in 3D tissue engineering, growing government funding for medical & academic research, surge in advancements in stem cell research, rise in clinical studies within the field of regenerative medicine and tissue engineering, and increasing introduction of tissue engineered novel products are the major factors propelling the market growth.
Tissue engineering is a multidisciplinary area that integrates concepts from engineering and life sciences to create biological replacements that enhance, sustain, or enhance tissue functionality. Therefore, increasing introduction of tissue engineered novel products is predicted to boost the market growth during the forecast period. For instance, in September 2023, EPIEFFECT launched by MIMEDX Group Inc. to broaden its portfolio of advanced wound care products. EPIEFFECT is a freeze-dried allograft derived from human placental tissue, comprising both amnion and chorion membranes.
By material type, biologically derived materials was the highest revenue-grossing segment in the global tissue engineering market in 2023 owing to the growing launch of new products. Biomaterials are crucial in the advancement of tissue engineering and biomedical devices, facilitating the natural enhancement of tissue regeneration to address bodily deterioration. Biologically sourced materials are utilized to generate neo-tissues in laboratory settings, mirroring the properties of their original bodily counterparts. These materials aid in tissue regeneration by precisely delivering specific chemokines to injury sites and providing temporary biodegradable support matrices with natural and functional attributes resembling tissues. For instance, in May 2023, AlloSource introduced AlloMend Duo Acellular Dermal Matrix (ADM), aimed at assisting surgeons in addressing and reconstructing soft tissue defects by providing durable structural support over the long term. Additionally, synthetic material is predicted to grow at the fastest CAGR during the forecast period. In tissue engineering, synthetic scaffolds are essential for controlling cell proliferation during the creation of synthetic tissues. These scaffolds, available in both two-dimensional (2D) and three-dimensional (3D) varieties, are highly effective in regulating cell growth. By incorporating biomimetic components, synthetic scaffolds can be assembled into functional structures that aid in the restoration, protection, or enhancement of injured organs or organ systems. This factor contributes to the revenue growth of this segment.
By application, orthopedics, musculoskeletal, & spine was the highest revenue-grossing segment in the global tissue engineering market in 2023 owing to the rise in musculoskeletal disorders, growing adoption of various growth strategies by market players, and increase in the introduction of new products. For instance, in October 2022, During the North American Spine Society (NASS) 2022 Annual Meeting in Chicago, LifeNet Health showcased the most recent innovations in allograft biologics for fusion. Their display highlighted ViviGen MIS, the first viable cellular allograft delivery device tailored specifically for minimally invasive surgery. Additionally, cardiology & vascular is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of cardiovascular conditions, heightened emphasis on developing stem cell therapies designed to repair, restore, & re-vascularize damaged heart tissues, expanding research & development efforts into gene therapy, advanced biologics, & small molecules to stimulate the regeneration of damaged heart cells.
By end-user, ambulatory surgical centers was the highest revenue-grossing segment in the global tissue engineering market in 2023 owing to the increasing trend towards the use of advanced surgical technologies, growing demand for more efficient surgical procedures and rise in the introduction of novel products. For instance, in May 2022, Rousselot, the health brand of Darling Ingredients, unveiled Quali-Pure HGP 2000, an innovative pharmaceutical-grade gelatin meticulously developed for applications in vaccinations and wound healing. Additionally, healthcare & medical institutes is predicted to grow at the fastest CAGR during the forecast period owing to the rising emphasis on research & development in tissue engineering and increase in the development of innovative tissue-based products.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing awareness of stem cell therapy, heightened prevalence of chronic illnesses, surge in sophisticated technology for diagnosing & treating chronic conditions, progressing advancements in 3D tissue engineering, and rise in the introduction of new products. For instance, in April 2022, Organogenesis, a prominent player in regenerative medicine, showcased their recent progress in wound care research at the 2022 Symposium on Advanced Wound Care Conference in Phoenix, Arizona. Their presentation highlighted advancements in products such as Affinity, PuraPly AM, Apligraf, and Organogenesis Physician Solutions. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising technological advancements in tissue engineering, growing incidence of clinical disorders such as cancer, increase in medical tourism, and regulatory bodies are approving a greater number of innovative products. For instance, in July 2023, Teijin Limited introduced SYNFOLIUM, a cardiovascular surgical patch, and obtained approval for manufacturing and marketing in Japan. This patch is utilized in the surgical management of congenital heart disease (CHD).
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Tissue engineering is a multidisciplinary area that integrates concepts from engineering and life sciences to create biological replacements that enhance, sustain, or enhance tissue functionality. Therefore, increasing introduction of tissue engineered novel products is predicted to boost the market growth during the forecast period. For instance, in September 2023, EPIEFFECT launched by MIMEDX Group Inc. to broaden its portfolio of advanced wound care products. EPIEFFECT is a freeze-dried allograft derived from human placental tissue, comprising both amnion and chorion membranes.
By material type, biologically derived materials was the highest revenue-grossing segment in the global tissue engineering market in 2023 owing to the growing launch of new products. Biomaterials are crucial in the advancement of tissue engineering and biomedical devices, facilitating the natural enhancement of tissue regeneration to address bodily deterioration. Biologically sourced materials are utilized to generate neo-tissues in laboratory settings, mirroring the properties of their original bodily counterparts. These materials aid in tissue regeneration by precisely delivering specific chemokines to injury sites and providing temporary biodegradable support matrices with natural and functional attributes resembling tissues. For instance, in May 2023, AlloSource introduced AlloMend Duo Acellular Dermal Matrix (ADM), aimed at assisting surgeons in addressing and reconstructing soft tissue defects by providing durable structural support over the long term. Additionally, synthetic material is predicted to grow at the fastest CAGR during the forecast period. In tissue engineering, synthetic scaffolds are essential for controlling cell proliferation during the creation of synthetic tissues. These scaffolds, available in both two-dimensional (2D) and three-dimensional (3D) varieties, are highly effective in regulating cell growth. By incorporating biomimetic components, synthetic scaffolds can be assembled into functional structures that aid in the restoration, protection, or enhancement of injured organs or organ systems. This factor contributes to the revenue growth of this segment.
By application, orthopedics, musculoskeletal, & spine was the highest revenue-grossing segment in the global tissue engineering market in 2023 owing to the rise in musculoskeletal disorders, growing adoption of various growth strategies by market players, and increase in the introduction of new products. For instance, in October 2022, During the North American Spine Society (NASS) 2022 Annual Meeting in Chicago, LifeNet Health showcased the most recent innovations in allograft biologics for fusion. Their display highlighted ViviGen MIS, the first viable cellular allograft delivery device tailored specifically for minimally invasive surgery. Additionally, cardiology & vascular is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of cardiovascular conditions, heightened emphasis on developing stem cell therapies designed to repair, restore, & re-vascularize damaged heart tissues, expanding research & development efforts into gene therapy, advanced biologics, & small molecules to stimulate the regeneration of damaged heart cells.
By end-user, ambulatory surgical centers was the highest revenue-grossing segment in the global tissue engineering market in 2023 owing to the increasing trend towards the use of advanced surgical technologies, growing demand for more efficient surgical procedures and rise in the introduction of novel products. For instance, in May 2022, Rousselot, the health brand of Darling Ingredients, unveiled Quali-Pure HGP 2000, an innovative pharmaceutical-grade gelatin meticulously developed for applications in vaccinations and wound healing. Additionally, healthcare & medical institutes is predicted to grow at the fastest CAGR during the forecast period owing to the rising emphasis on research & development in tissue engineering and increase in the development of innovative tissue-based products.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing awareness of stem cell therapy, heightened prevalence of chronic illnesses, surge in sophisticated technology for diagnosing & treating chronic conditions, progressing advancements in 3D tissue engineering, and rise in the introduction of new products. For instance, in April 2022, Organogenesis, a prominent player in regenerative medicine, showcased their recent progress in wound care research at the 2022 Symposium on Advanced Wound Care Conference in Phoenix, Arizona. Their presentation highlighted advancements in products such as Affinity, PuraPly AM, Apligraf, and Organogenesis Physician Solutions. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising technological advancements in tissue engineering, growing incidence of clinical disorders such as cancer, increase in medical tourism, and regulatory bodies are approving a greater number of innovative products. For instance, in July 2023, Teijin Limited introduced SYNFOLIUM, a cardiovascular surgical patch, and obtained approval for manufacturing and marketing in Japan. This patch is utilized in the surgical management of congenital heart disease (CHD).
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Material Type, Application, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
Segmentation: Tissue Engineering Market Report 2023 - 2034
Tissue Engineering Market Analysis & Forecast by Material Type 2023 - 2034 (Revenue USD Bn)
- Biologically Derived Materials
- Collagen
- Others
- Synthetic Material
- Synthetic Polymers
- Others
- Others
Tissue Engineering Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Orthopedics, Musculoskeletal, & Spine
- Cord Blood & Cell Banking
- Skin & Integumentary
- Cardiology & Vascular
- GI, Gynecology
- Neurology
- Urology
- Cancer
- Dental
- Others
Tissue Engineering Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Healthcare & Medical Institutes
- Ambulatory Surgical Centers
- Regenerative Medicine Research
- Others
Tissue Engineering Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Tissue Engineering Market: Material Type Estimates & Trend Analysis
8. Tissue Engineering Market: Application Estimates & Trend Analysis
9. Tissue Engineering Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Tissue Engineering Market
12. Europe Global Tissue Engineering Market
13. Asia Pacific Global Tissue Engineering Market
14. Latin America Global Tissue Engineering Market
15. MEA Global Tissue Engineering Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- AbbVie (Allergan)
- Integra LifeSciences Corporation
- Becton Dickinson and Company
- Tissue Regenix Group plc
- Organogenesis Holdings Inc.
- Baxter International Inc.
- ACell Inc.
- Stryker Corporation
- Athersys Inc.
- B. Braun
- Zimmer Biomet Holdings Inc.
- Medtronic
- ReproCell Inc.
- RTI Surgical Inc.
